The Latest
-
Spencer Platt via Getty Images
Medicare’s next list of drugs for price negotiation could get ‘very interesting’ — and have a bigger impact on pharma
The Biden-era law is now in the hands of a new administration, and drugmakers are scanning the horizon for hints of a massive overhaul or incremental change.
-
Stock via Getty Images
In the crowded cardio space, it’s David vs. Goliath for small biotechs
What will it take for a clinical-stage biotech to break into the cardio space? One CEO thinks he has the answer.
-
Stock via Getty Images
The kids are alright: How pharma can make inroads with Gen Z
As drug development priorities shift, pharma companies need to understand younger patients to improve their reputation.
-
Permission granted by Fractyl Health
Q&A // Biotech SpotlightBeyond GLP-1s? This biotech is exploring longer-term metabolic treatments
Fractyl Health is entering pivotal studies for a procedure that aims to be an ‘off ramp’ to GLP-1s and exploring how a one-time, ‘smart GLP-1’ gene therapy can Treat type 2 diabetes.
-
Anatolii Kovalov via Getty Images
Tariffs raise concern among generic drugmakers, and advocacy groups are seeking exemptions
While the 10% tariff on Chinese goods won’t have too much impact on branded drugs, generics are struggling to pivot.
-
Permission granted by Bristol Myers Squibb
Bristol Myers gives first peek at closely watched launch of schizophrenia drug
Cobenfy, the main asset acquired through Bristol Myers’ $14 billion purchase of Karuna, had $10 million in sales in the fourth quarter and around 1,000 prescriptions weekly by late January.
-
cagkansayin via Getty Images
With uncertainty roiling Big Pharma, execs are placing lower-risk bets
The market has been no less demanding for pharma giants as 2025 begins, but last year’s strategies are paying off.
-
Stock via Getty Images
As financial headwinds pick up, pharmas are aiming to squeeze more ROI from their R&D
With assets under a knife and pipelines under a microscope, R&D programs are being overhauled to be more efficient and cost effective.
-
Win McNamee via Getty Images
RFK Jr. will face these critical tests if confirmed as head of the HHS
After a Senate committee advanced President Trump’s nominee to lead HHS, Robert F. Kennedy Jr. is poised to secure the top job at the nation’s healthcare agency.
-
David McNew/Getty Images via Getty Images
Looming USAID shutdown threatens global health presence and a legacy of medical foreign aid
As President Trump and his cohorts plan to shut down the U.S. Agency for International Development, here’s what that could mean for global health and the drugmaking industry.
-
Sarah Silbiger via Getty Images
What should pharma make of the FDA going dark on DEI?
After a series of potent executive orders last week, the FDA removed draft guidance on diversity in clinical trials.
-
David McNew via Getty Images
Drugmakers prep for bird flu outbreak, despite continued low risk
While the virus hasn’t made a sustained leap into humans, vaccines and treatments are coming through the pipes if it does.
-
Permission granted by Vertex Pharmaceuticals
Deep DiveA new, non-opioid pain drug is here. Getting it to patients could be agony.
After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful biotechs contend with a healthcare system that’s long favored opioids?
-
Anna Moneymaker via Getty Images
Is federal funding frozen? Has it already thawed? Flip-flop leaves biopharma on edge
NIH grants that help fund drug development were caught in the mix of confusing executive orders this week.
-
Stock via Getty Images
Year in PreviewPharma’s forecast for 2025: Sowing seeds of a rebound
Despite regulatory uncertainty, pharma is bouncing back from a market slump and is being fueled by innovation.
-
Win McNamee via Getty Images
RFK Jr. faces reconciliation of past vaccine statements at Senate HHS hearing
“Are you supportive of these onesies?” Sen. Bernie Sanders asked Kennedy, pointing to infant clothing stamped with anti-vaccine slogans — and more from yesterday’s confirmation hearing.
-
Courtesy of Vertex Pharmaceuticals
A long-awaited alternative to opioids is on the FDA doorstep. Can Vertex seal the deal?
Vertex Pharmaceuticals’ non-opioid pain medication is up for FDA approval this week. Other drugmakers have found safer alternatives to expand the pain management landscape.
Updated Feb. 4, 2025 -
iStock via Getty Images
Bringing drugs to market has ‘never been more challenging,’ and pharma is learning to adapt
As changes to the U.S. regulatory foundation take hold, pharmas need to change their strategies to keep innovation — and the bottom line — above the surface.
-
Permission granted by Klein Hersh
Executive hiring changes reflect a broader biotech comeback
Executive hiring shifts are often indicators of wider trends in the market. Here’s how the hiring landscape for pharma leaders is changing.
-
Permission granted by Coya Therapeutics
Q&A // First 90 DaysAn ALS treatment wave is approaching, and this biotech CEO is ready to surf
Coya Therapeutics is entering into a phase 2b study for its ALS, and the biotech’s CEO believes it’s on the cusp of a game changer.
-
Stock via Getty Images
Natural killer cells, a rising alternative to CAR-T cell therapy
These innate immune cells may provide a safer, lower-cost option in cancer and autoimmune diseases.
-
Stock via Getty Images
Gene therapies have been uneven for DMD — but these companies hope to turn the tide
Despite mixed results using gene therapies to treat Duchenne muscular dystrophy, drug developers are pushing ahead with the belief the answer could come down to delivery.
-
E+ via Getty Images
J&J is all in on tau-targeted Alzheimer’s candidates. Will the approach lead to more effective treatments?
Anti-tau candidates haven’t crossed the regulatory threshold like their anti-amyloid counterparts, but J&J’s clinical efforts could lead in the right direction.
-
Permission granted by BioAge Labs
After an obesity stumble, BioAge reconnects with its longevity pipeline
The company is kicking off the year with a new Novartis partnership and renewed focus on metabolic aging targets.
-
Stock via Getty Images
Innovate or perish: Industry’s evolution leaves little room for me-too approaches
Novel drug approvals have set the stage for more breakthroughs in pharma.
Updated Jan. 22, 2025
